Cargando…

Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes

AIMS: To identify clinically meaningful clusters of patients with similar glycated hemoglobin (HbA1c) trajectories among patients with type 2 diabetes. METHODS: A retrospective cohort study using unsupervised machine learning clustering methodologies to determine clusters of patients with similar lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karpati, Tomas, Leventer-Roberts, Maya, Feldman, Becca, Cohen-Stavi, Chandra, Raz, Itamar, Balicer, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235308/
https://www.ncbi.nlm.nih.gov/pubmed/30427908
http://dx.doi.org/10.1371/journal.pone.0207096
_version_ 1783370854622560256
author Karpati, Tomas
Leventer-Roberts, Maya
Feldman, Becca
Cohen-Stavi, Chandra
Raz, Itamar
Balicer, Ran
author_facet Karpati, Tomas
Leventer-Roberts, Maya
Feldman, Becca
Cohen-Stavi, Chandra
Raz, Itamar
Balicer, Ran
author_sort Karpati, Tomas
collection PubMed
description AIMS: To identify clinically meaningful clusters of patients with similar glycated hemoglobin (HbA1c) trajectories among patients with type 2 diabetes. METHODS: A retrospective cohort study using unsupervised machine learning clustering methodologies to determine clusters of patients with similar longitudinal HbA1c trajectories. Stability of these clusters was assessed and supervised random forest analysis verified the clusters’ reproducibility. Clinical relevance of the clusters was assessed through multivariable analysis, comparing differences in risk for a composite outcome (macrovascular and microvascular outcomes, hypoglycemic events, and all-cause mortality) at HbA1c thresholds for each cluster. RESULTS: Among 60,423 patients, three clusters of HbA1c trajectories were generated: stable (n = 45,679), descending (n = 6,084), and ascending (n = 8,660) trends, which were reproduced with 99.8% accuracy using a random forest model. In the clinical relevance assessment, HbA1c levels demonstrated a J-shape association with the risk for outcomes. HbA1c level thresholds for minimizing outcomes’ risk differed by cluster: 6.0–6.4% for the stable cluster, <8.0% for the descending cluster, and <9.0 for the ascending cluster. CONCLUSIONS: By applying unsupervised machine learning to longitudinal HbA1c trajectories, we have identified clusters of patients who have distinct risk for diabetes-related complications. These clusters can be the basis for developing individualized models to personalize glycemic targets.
format Online
Article
Text
id pubmed-6235308
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62353082018-12-01 Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes Karpati, Tomas Leventer-Roberts, Maya Feldman, Becca Cohen-Stavi, Chandra Raz, Itamar Balicer, Ran PLoS One Research Article AIMS: To identify clinically meaningful clusters of patients with similar glycated hemoglobin (HbA1c) trajectories among patients with type 2 diabetes. METHODS: A retrospective cohort study using unsupervised machine learning clustering methodologies to determine clusters of patients with similar longitudinal HbA1c trajectories. Stability of these clusters was assessed and supervised random forest analysis verified the clusters’ reproducibility. Clinical relevance of the clusters was assessed through multivariable analysis, comparing differences in risk for a composite outcome (macrovascular and microvascular outcomes, hypoglycemic events, and all-cause mortality) at HbA1c thresholds for each cluster. RESULTS: Among 60,423 patients, three clusters of HbA1c trajectories were generated: stable (n = 45,679), descending (n = 6,084), and ascending (n = 8,660) trends, which were reproduced with 99.8% accuracy using a random forest model. In the clinical relevance assessment, HbA1c levels demonstrated a J-shape association with the risk for outcomes. HbA1c level thresholds for minimizing outcomes’ risk differed by cluster: 6.0–6.4% for the stable cluster, <8.0% for the descending cluster, and <9.0 for the ascending cluster. CONCLUSIONS: By applying unsupervised machine learning to longitudinal HbA1c trajectories, we have identified clusters of patients who have distinct risk for diabetes-related complications. These clusters can be the basis for developing individualized models to personalize glycemic targets. Public Library of Science 2018-11-14 /pmc/articles/PMC6235308/ /pubmed/30427908 http://dx.doi.org/10.1371/journal.pone.0207096 Text en © 2018 Karpati et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Karpati, Tomas
Leventer-Roberts, Maya
Feldman, Becca
Cohen-Stavi, Chandra
Raz, Itamar
Balicer, Ran
Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes
title Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes
title_full Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes
title_fullStr Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes
title_full_unstemmed Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes
title_short Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes
title_sort patient clusters based on hba1c trajectories: a step toward individualized medicine in type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235308/
https://www.ncbi.nlm.nih.gov/pubmed/30427908
http://dx.doi.org/10.1371/journal.pone.0207096
work_keys_str_mv AT karpatitomas patientclustersbasedonhba1ctrajectoriesasteptowardindividualizedmedicineintype2diabetes
AT leventerrobertsmaya patientclustersbasedonhba1ctrajectoriesasteptowardindividualizedmedicineintype2diabetes
AT feldmanbecca patientclustersbasedonhba1ctrajectoriesasteptowardindividualizedmedicineintype2diabetes
AT cohenstavichandra patientclustersbasedonhba1ctrajectoriesasteptowardindividualizedmedicineintype2diabetes
AT razitamar patientclustersbasedonhba1ctrajectoriesasteptowardindividualizedmedicineintype2diabetes
AT balicerran patientclustersbasedonhba1ctrajectoriesasteptowardindividualizedmedicineintype2diabetes